KHPG(SZ:002773)2024-10-24 10:37Financial Performance - The company's operating revenue for Q3 2024 reached ¥1,117,161,543.56, representing a 3.59% increase year-over-year[2] - Net profit attributable to shareholders decreased by 6.18% to ¥281,491,538.10 in Q3 2024, while year-to-date net profit increased by 17.97% to ¥973,711,578.04[2] - The total assets at the end of Q3 2024 amounted to ¥9,212,829,093.44, reflecting an 8.01% increase compared to the end of the previous year[2] - The total comprehensive income for the period reached CNY 973,563,490.82, an increase from CNY 825,156,266.48 in the previous period, representing a growth of approximately 17.9%[18] - Basic and diluted earnings per share were both CNY 1.06, up from CNY 0.90 in the same period last year, indicating a 17.8% increase[18] Research and Development - The company reported a significant increase in R&D expenses, which rose by 32.44% to ¥342,158,088.75 compared to the previous year[7] - Research and development expenses increased to CNY 342,158,088.75, compared to CNY 258,348,158.90, marking a rise of 32.5%[16] Cash Flow - The cash flow from operating activities for the year-to-date period increased by 24.72% to ¥1,254,467,611.62[2] - Cash flow from operating activities generated CNY 1,254,467,611.62, compared to CNY 1,005,804,614.23 in the previous year, reflecting a growth of 24.7%[19] - The total cash inflow from operating activities was CNY 3,684,526,280.03, compared to CNY 3,263,788,643.99 in the previous year, marking an increase of 12.9%[19] - Cash inflow from investment activities totaled CNY 2,132,043,970.54, down from CNY 2,729,377,175.51, a decrease of approximately 21.9%[20] - The net cash flow from investment activities was -CNY 2,316,936,761.18, worsening from -CNY 1,951,455,806.19 in the previous year[20] - The company reported a cash outflow from financing activities of -CNY 343,198,374.48, compared to -CNY 130,346,613.38 in the previous year, indicating a significant increase in cash outflow[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 32,446[8] - Chengdu Kanghong Technology Industry (Group) Co., Ltd. holds 31.75% of shares, totaling 292,014,900 shares[8] - The top ten shareholders hold a combined total of 92.43% of the shares[8] Assets and Liabilities - The total current assets increased to approximately ¥6.20 billion from ¥5.31 billion[13] - The accounts receivable increased to approximately ¥174.09 million from ¥160.41 million[13] - The inventory at the end of the reporting period was approximately ¥404.42 million, slightly up from ¥403.61 million[13] - The company's total liabilities increased to CNY 778,248,708.06 from CNY 717,763,862.41, representing an increase of 8.4%[15] - Deferred income tax assets decreased to CNY 242,661,487.49 from CNY 358,078,120.48, a decline of 32.3%[15] Market and Product Development - The company plans to continue expanding its market presence and invest in new product development to drive future growth[17] - The proportion of revenue from traditional Chinese medicine products was 30.68%, with a year-over-year growth of 5.03%[3] - The company experienced a 104.93% increase in revenue from medical devices, reaching ¥1,392.92[3] - The company has received approval for the listing application of fumaric acid volasertib from the National Medical Products Administration[12] - The company also received a drug registration certificate for fumaric acid volasertib tablets on July 17, 2024[12]